drugset / Trial / NCT00398554
Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma
Phase 2
Completed
16 enrolled
Christine Mauz-Körholz
Martin-Luther-Universität Halle-Wittenberg · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects and how well combination chemotherapy works in treating young male patients with Hodgkin's lymphoma.
Timeline
- Start
- 2005-06
- Primary completion
- 2012-10
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 1250 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Prednisone | Other / unclassified | 40 mg/m2 | Oral |
| Subject | Vinblastine | Small molecule | 6 mg/m2 | Intravenous |
| Subject | Vincristine | Small molecule | 1.5 mg/m2 | Intravenous |